Stockscreener 앱 받기
25.77
0.43%
-0.015
전일 마감가:
$25.78
열려 있는:
$25.36
하루 거래량:
4,317
Relative Volume:
0.01
시가총액:
$363.54M
수익:
-
순이익/손실:
$-19.48M
주가수익비율:
-17.60
EPS:
-1.4641
순현금흐름:
$-8.59M
1주 성능:
+16.52%
1개월 성능:
-4.00%
6개월 성능:
+149.22%
1년 성능:
+160.34%
1일 변동 폭
$25.36
$26.24
1주일 범위
$21.00
$26.61
52주 변동 폭
$7.78
$34.10
그리니치 Stock (GLSI) Company Profile
명칭
Greenwich Lifesciences Inc
전화
203-434-3290
주소
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
26.24 | 357.17M | 0 | -19.48M | -8.59M | -1.4641 |
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.04 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.53 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.40 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.52 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
그리니치 Stock (GLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | Noble Capital Markets | Outperform |
| 2021-09-01 | 개시 | H.C. Wainwright | Buy |
그리니치 주식(GLSI)의 최신 뉴스
Greenwich Lifesciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView — Track All Markets
Aug Retail: Will Greenwich LifeSciences Inc benefit from current market trendsTrade Risk Assessment & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Will Greenwich LifeSciences Inc benefit from current market trends2026 Market Outlook & Weekly Hot Stock Watchlists - baoquankhu1.vn
(GLSI) Risk Channels and Responsive Allocation - Stock Traders Daily
GLSI Technical Analysis | Trend, Signals & Chart Patterns | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim - Seeking Alpha
Greenwich LifeSciences files patent claims for breast cancer therapy By Investing.com - Investing.com South Africa
Greenwich LifeSciences advances new patent claims after FLAMINGO-01 data show statistically significant immune response - Traders Union
Greenwich LifeSciences files patent claims for breast cancer therapy - Investing.com
Greenwich Lifesciences Provides Update On Patent Claims Potentially Doubling Gp2 Market Potential - TradingView
Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential - The Manila Times
Greenwich LifeSciences Provides Update On Patent Claims Potentially Doubling GP2 Market Potential - marketscreener.com
Valuation Update: Can Greenwich LifeSciences Inc expand into new marketsMarket Sentiment Report & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Greenwich LifeSciences Delays Annual SEC Filing - TipRanks
Greenwich LifeSciences (GLSI) notifies SEC of late 10-K, cites higher R&D - Stock Titan
Sell Signal: What are the future prospects of Greenwich LifeSciences Inc2026 Market Overview & Long-Term Investment Growth Plans - baoquankhu1.vn
(GLSI) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Greenwich LifeSciences (GLSI) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Aug Analyst Calls: What are the future prospects of Greenwich LifeSciences IncPortfolio Value Summary & Real-Time Market Trend Scan - baoquankhu1.vn
If You Invested $1,000 in Greenwich Lifesciences Inc (GLSI) - Stock Titan
Retail Trends: Is Greenwich LifeSciences Inc undervalued by DCF analysisGold Moves & Weekly Top Performers Watchlists - baoquankhu1.vn
Treasury Yields: Is Greenwich LifeSciences Inc a turnaround storyWeekly Profit Analysis & Long Hold Capital Preservation Plans - baoquankhu1.vn
Greenwich LifeSciences expands Phase III trial to City of Hope sites - ca.investing.com
Greenwich LifeSciences Inc initiates new US clinical sites for Flamingo-01 phase III trial - marketscreener.com
Greenwich LifeSciences, Inc. Announces Addition of City of Hope to Flamingo-01 - marketscreener.com
Greenwich LifeSciences Expands FLAMINGO-01 Trial to City of Hope - National Today
Greenwich LifeSciences expands Phase III trial to City of Hope sites By Investing.com - Investing.com India
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01 - ChartMill
Liquidity Mapping Around (GLSI) Price Events - Stock Traders Daily
Greenwich LifeSciences to present trial data at AACR meeting By Investing.com - Investing.com South Africa
Greenwich LifeSciences to present trial data at AACR meeting - Investing.com
Greenwich Lifesciences provides update on upcoming AACR meeting - marketscreener.com
Greenwich Lifesciences Provides Update On Upcoming Aacr Meeting - TradingView
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting - manilatimes.net
Greenwich LifeSciences, Inc. Announces Presentation of FLAMINGO-01 Phase III Clinical Trial Data at AACR Meeting 2026 - Quiver Quantitative
Greenwich LifeSciences to share AACR Meeting plans - Traders Union
Greenwich LifeSciences reports reduced cancer recurrence in trial By Investing.com - Investing.com South Africa
Why is GLSI stock rising today? - MSN
Breakthrough in Clinical Trial Data: Biopharmaceutical company Greenwich Lifesciences Inc (NASDAQ: GLSI) recently announced the latest analysis results of its core immunotherapy GP2 in adjuvant treatment for breast cancer. - Bitget
Why Is GLSI Stock Rising Today? - Mena FN
Greenwich LifeSciences reports reduced cancer recurrence in trial - Investing.com
Greenwich LifeSciences provides update showing continued reduction in recurrence rate in the open label arm of Flamingo-01 - marketscreener.com
Greenwich Lifesciences Provides Update Showing Continued Reduction In Recurrence Rate In The Open Label Arm Of Flamingo-01 - TradingView
Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01 - manilatimes.net
Greenwich LifeSciences Provides Update Showing Continued - GlobeNewswire
Greenwich LifeSciences begins using commercial GP2 at US sites By Investing.com - Investing.com Australia
Greenwich LifeSciences begins using commercial GP2 at US sites - Investing.com
그리니치 (GLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
그리니치 주식 (GLSI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Jan 12 '26 |
Buy |
27.54 |
2,900 |
79,866 |
5,602,302 |
| Patel Snehal | CEO and CFO |
Dec 31 '25 |
Buy |
21.36 |
4,300 |
91,848 |
5,599,402 |
| Patel Snehal | CEO and CFO |
Dec 30 '25 |
Buy |
21.73 |
2,900 |
63,017 |
5,595,102 |
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
| Patel Snehal | CEO and CFO |
Nov 07 '25 |
Buy |
8.43 |
10,600 |
89,358 |
5,583,502 |
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
| Patel Snehal | CEO and CFO |
Apr 25 '25 |
Buy |
9.88 |
3,600 |
35,568 |
5,570,602 |
| Patel Snehal | CEO and CFO |
Apr 17 '25 |
Buy |
8.98 |
5,400 |
48,492 |
5,567,002 |
0.62%
0.89%
자본화:
|
볼륨(24시간):